Cue Biopharma
CUE
92 hedge funds and large institutions have $294M invested in Cue Biopharma in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 23 reducing their positions, and 17 closing their positions.
74% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 23
40% more call options, than puts
Call options by funds: $636K | Put options by funds: $453K
0.33% more ownership
Funds ownership: 1.88% → 2.21% (+0.33%)
7% less funds holding
Funds holding: 99 → 92 (-7)
25% less capital invested
Capital invested by funds: $393M → $294M (-$99.2M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$14.9M |
| 2 |
SPC
Slate Path Capital
New York
|
+$11.8M |
| 3 |
RSWM
Robertson Stephens Wealth Management
San Francisco,
California
|
+$9.3M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$7.68M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.56M |
| 2 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.46M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.14M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.06M |
| 5 |
Citigroup
New York
|
-$837K |
CUE Hedge Fund Activity: Q3 2020 in Review
92 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2020, worth a combined $294M — down 25% from $393M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CUE and 11 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 40 added.
The largest buyer was Corriente Advisors, adding an estimated $14.9M. The largest seller was Federated Hermes, cutting an estimated $4.56M.
- 92 institutional investors held Cue Biopharma (CUE) as of Q3 2020, down from 99 in Q2 2020.
- Funds reported $294M of Cue Biopharma stock for Q3 2020, down 25% quarter-over-quarter.
- 11 funds opened new Cue Biopharma positions in Q3 2020 and 17 closed out, a net change of -6 holders.
- The largest Cue Biopharma buyer in Q3 2020 was Corriente Advisors, an estimated $14.9M added.
- The largest Cue Biopharma seller in Q3 2020 was Federated Hermes, an estimated $4.56M sold.
Based on aggregated 13F filings for Q3 2020.